PMID- 21916526 OWN - NLM STAT- MEDLINE DCOM- 20120803 LR - 20190116 IS - 1029-2403 (Electronic) IS - 1026-8022 (Linking) VI - 53 IP - 3 DP - 2012 Mar TI - Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. PG - 406-10 LID - 10.3109/10428194.2011.623254 [doi] AB - Polymorphisms of the Glutathione-S Transferase (GST) family may influence the prognosis in lymphoma patients. We aimed to validate the impact of GSTT1 and GSTM1 deletions and of the GSTP1Ile105Val polymorphism on outcome and toxicity in 140 patients with advanced Hodgkin's lymphoma enrolled in the prospective multicenter HD2000-GISL trial, comparing ABVD, BEACOPP and CEC regimens. Carriers of the GSTP1Ile105Val polymorphism had a higher rate of grade 3-4 anemia following treatment. Overall, our study failed to validate GST genotyping as prognostic factor for progression-free survival (PFS). Only the small cohort of patients with an international prognostic score (IPS) >3 and undeleted GSTT1 and/or GSTM1, treated with ABVD had worse progression-free survival (PFS) (GSTT1 + vs GSTT1-: HR 5.02, 95% C.I., 1.16-21.8, p = 0.031, GSTM1 + /GSTT1 + vs GSTM1-and/or GSTT1-: HR 4.61, 95% C.I. 1.28- 16.6, p = 0.019, respectively). No differences were observed for patients treated with intensified regimens, as BEACOPP and CEC. In conclusion, the prognostic role of GST polymorphism, if at all, is limited to a small subgroup of patients treated with standard ABVD regimen. FAU - Morabito, Fortunato AU - Morabito F AD - UOC di Ematologia, Dipartimento Oncoematologico, Azienda Ospedaliera, Cosenza, Italy. fortunato_morabito@tin.it FAU - Hohaus, Stefan AU - Hohaus S FAU - Mammi, Corrado AU - Mammi C FAU - Marcheselli, Luigi AU - Marcheselli L FAU - Gentile, Massimo AU - Gentile M FAU - Merli, Francesco AU - Merli F FAU - Montanini, Antonella AU - Montanini A FAU - Stelitano, Caterina AU - Stelitano C FAU - La Sala, Antonio AU - La Sala A FAU - Scalone, Renato AU - Scalone R FAU - Voso, Maria Teresa AU - Voso MT FAU - Luminari, Stefano AU - Luminari S FAU - Iannitto, Emilio AU - Iannitto E FAU - Gobbi, Paolo AU - Gobbi P FAU - Federico, Massimo AU - Federico M LA - eng PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - United States TA - Leuk Lymphoma JT - Leukemia & lymphoma JID - 9007422 RN - 0 (Neoplasm Proteins) RN - 11056-06-7 (Bleomycin) RN - 35S93Y190K (Procarbazine) RN - 3Z8479ZZ5X (Epirubicin) RN - 5J49Q6B70F (Vincristine) RN - 5V9KLZ54CY (Vinblastine) RN - 6PLQ3CP4P3 (Etoposide) RN - 7BRF0Z81KG (Lomustine) RN - 7GR28W0FJI (Dacarbazine) RN - 80168379AG (Doxorubicin) RN - 8N3DW7272P (Cyclophosphamide) RN - BG3F62OND5 (Carboplatin) RN - EC 2.5.1.- (glutathione S-transferase T1) RN - EC 2.5.1.18 (GSTP1 protein, human) RN - EC 2.5.1.18 (Glutathione S-Transferase pi) RN - EC 2.5.1.18 (Glutathione Transferase) RN - EC 2.5.1.18 (glutathione S-transferase M1) RN - RSA8KO39WH (Vindesine) RN - VB0R961HZT (Prednisone) RN - ABVD protocol RN - BEACOPP protocol RN - CAD protocol 2 RN - CEC protocol RN - COPP protocol RN - EBV protocol SB - IM MH - Adult MH - Anemia/chemically induced/genetics MH - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/pharmacokinetics/therapeutic use MH - Biotransformation/genetics MH - Bleomycin/administration & dosage/adverse effects/pharmacokinetics MH - Carboplatin/administration & dosage/adverse effects/pharmacokinetics MH - Cyclophosphamide/administration & dosage/adverse effects/pharmacokinetics MH - Dacarbazine/administration & dosage/adverse effects/pharmacokinetics MH - Doxorubicin/administration & dosage/adverse effects/pharmacokinetics MH - Epirubicin/administration & dosage/adverse effects/pharmacokinetics MH - Etoposide/administration & dosage/adverse effects/pharmacokinetics MH - Female MH - Gene Deletion MH - Genetic Predisposition to Disease MH - Genotype MH - Glutathione S-Transferase pi/*genetics/physiology MH - Glutathione Transferase/*genetics/physiology MH - Hodgkin Disease/drug therapy/*enzymology/genetics/mortality MH - Humans MH - Lomustine/administration & dosage/adverse effects/pharmacokinetics MH - Male MH - Middle Aged MH - Neoplasm Proteins/*genetics/physiology MH - *Polymorphism, Genetic MH - Polymorphism, Single Nucleotide MH - Prednisone/administration & dosage/adverse effects/pharmacokinetics MH - Procarbazine/administration & dosage/adverse effects/pharmacokinetics MH - Prognosis MH - Treatment Outcome MH - Vinblastine/administration & dosage/adverse effects/pharmacokinetics MH - Vincristine/administration & dosage/adverse effects/pharmacokinetics MH - Vindesine/administration & dosage/adverse effects/pharmacokinetics EDAT- 2011/09/16 06:00 MHDA- 2012/08/04 06:00 CRDT- 2011/09/16 06:00 PHST- 2011/09/16 06:00 [entrez] PHST- 2011/09/16 06:00 [pubmed] PHST- 2012/08/04 06:00 [medline] AID - 10.3109/10428194.2011.623254 [doi] PST - ppublish SO - Leuk Lymphoma. 2012 Mar;53(3):406-10. doi: 10.3109/10428194.2011.623254.